Melgari, D., Zhang, Y. H., El Harchi, A., Dempsey, C. E., & Hancox, J. C. (2015). Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. *Journal of Molecular and Cellular Cardiology, 86*, 42-53. https://doi.org/10.1016/j.yjmcc.2015.06.021

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
10.1016/j.yjmcc.2015.06.021

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at http://www.sciencedirect.com/science/article/pii/S0022282815300055.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide

Dario Melgari, Yihong Zhang, Aziza El Harchi, Christopher E. Dempsey, Jules C. Hancox

Abstract

The class Ic antiarrhythmic drug flecainide inhibits KCNH2-encoded “hERG” potassium channels at clinically relevant concentrations. The aim of this study was to elucidate the underlying molecular basis of this action. Patch clamp recordings of hERG current (IhERG) were made from hERG expressing cells at 37 °C. Wild-type (WT) IhERG was inhibited with an IC50 of 1.49 μM and this was not significantly altered by reversing the direction of K+ flux or raising external [K+]. The use of charged and uncharged flecainide analogues showed that the charged form of the drug accesses the channel from the cell interior to produce block. Promotion of WT IhERG inactivation slowed recovery from inhibition, whilst the N588K and S631A attenuated-inactivation mutants exhibited IC50 values 4–5 fold that of WT IhERG. The use of pore-helix/selectivity filter (T623A, S624A V625A) and S6 helix (G648A, Y652A, F656A) mutations showed ~10-fold shifts in IC50 for all but V625A and F656A, which respectively exhibited IC50 values 27-fold and 142-fold their WT controls. Docking simulations using a MthK-based homology model suggested an allosteric effect of V625A, since in low energy conformations flecainide lay too low in the pore to interact directly with that residue. On the other hand, the molecule could readily form π–π stacking interactions with aromatic residues and particularly with F656. We conclude that flecainide accesses the hERG channel from the cell interior on channel gating, binding low in the inner cavity, with the S6 F656 residue acting as a principal binding determinant.

1. Introduction

Flecainide is a class Ic antiarrhythmic drug that is used primarily in the treatment of supraventricular arrhythmias [1] although, in the absence of structural heart disease, it is sometimes used in the treatment of ventricular tachycardias that are resistant to other treatment. Guidelines from the American College of Cardiology, American Heart Association and European Society of Cardiology, recommend flecainide as a front-line treatment option for pharmacological cardioversion of atrial fibrillation (AF) and for the maintenance of sinus rhythm in AF patients (e.g. [2–4]). A 2011 review of 25 years of flecainide use sup-ports the notion that, with appropriate patient selection, flecainide is safe and effective in AF management [5]. The importance of appropriate patient selection arises, to a significant extent, from the results of the CAST trial, which showed increased mortality with class Ic (flecainide and encainide) drug treatment of patients surviving myocardial infarction (MI) [6]. Recent evidence supports an additional clinical application of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), particularly in cases where arrhythmias are not completely suppressed by β-blocker therapy (e.g. [7–10]).

Flecainide’s class Ic action is attributable to the drug’s open state dependent Na channel block and its Na channel association/dissociation kinetics [1,5,11]. The drug can prolong ventricular and atrial action potentials (APs), but shortens Purkinje fibre APs (reviewed in [5]). Therapeutic serum levels of flecainide lie between ~0.5 and 2.4 μM [12]. Flecainide inhibits L-type calcium current at concentrations that considerably exceed this range (IC50 of ~20 μM; [13]). Flecainide may also act as an open-channel blocker and gating modifier of the RyR2 ryanodine receptor [7,14]. It is also an effective inhibitor of cardiac K+ channels [15]. For example, flecainide discriminates between Kv4.x and 1.4 channels that contribute to transient outward K+ current (being more effective against the former subtype; [16]). It has also been shown to inhibit the rapid delayed rectifier K+ current, Ikr [17–19] and recombinant channels encoded by human Ether-à-go-go-Related Gene (hERG; [20–24]). The agent’s IKr/hERG blockade occurs at concentrations that overlap the clinical concentration range [20,21,24] and, as noted by Aliot and colleagues, the drug’s inhibitory effects on INa and Ikr occur at lower concentrations than those on other channels [5]. They are therefore the ion channel effects that are likely to predominate during clinical use of the drug. Although rarely associated with Torsades de Pointes (TdP) arrhythmia or QT interval prolongation, some cases have been reported in which rate-corrected QT interval prolongation was not fully accounted for by widening of the QRS complex, and/or that
exhibited a reverse-rate/bradycardia dependence that is consistent with a role for \( I_{K} \) inhibition (e.g. [25–28]).

Flecainide has been reported to exhibit characteristics of a comparably rapidly acting, gated state dependent hERG channel blocker [20] and, in marked contrast to high affinity methanesulphonanilide inhibitors of hERG current (\( I_{hERG} \)) [29,30], flecainide block of \( I_{hERG} \) develops rapidly on membrane depolarization [20]. Other class I antiarrhythmics that have been investigated in detail have shown a restricted set of binding residues and a relatively modest dependence of hERG channel blockade on inactivation gating [31–34]. In contrast, data on the underlying basis of flecainide inhibition of \( I_{hERG} \) are at present lacking. The present study was conducted to address this deficit, through investigation of the role of \( I_{hERG} \) inactivation and the roles of major pore helix and N6 helical residues in flecainide’s inhibitory action.

2. Methods

2.1. Wild-type and mutant hERG channels

The mammalian cell line (Human Embryonic Kidney HEK293) stably expressing wild-type (WT) hERG channels was kindly donated by Prof Craig January [30]. The pore helix (T623A, S624A and V625A) and S6 helix (G648A and F656A) alanine mutants and the attenuated-inactivation mutants S631A, N588K and N588K/S631A were generated and used as described previously [33–36]. The HEK293 cell line stably expressing the hERG S6 helix mutant Y652A was used as described previously [35].

2.2. Maintenance of mammalian cells lines and cell transfection

HEK cells stably or transiently expressing hERG channel constructs were cultured as previously described [34,37]. The cells were plated in 40 mm petri dishes at least 48 h before transfection and incubated at 37 °C (5% CO2) for at least 24 h before electrophysiological recording.

2.3. Electrophysiology

Glass shards containing plated cells were placed in a recording chamber mounted on an inverted microscope (Nikon Diaphot, USA). The cells were continuously superfused with a pre-warmed (37 °C) standard Tyrode’s solution containing (in mM) the following: 140 NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10 glucose, 5 HEPES (titrated to pH 7.4 with NaOH). A modified “High K” version of this solution (containing 94 mM KCl and 50 mM NaCl) was used to elicit recordable currents from T623A, G648A and F656A hERG channels mutants [34,37]. Glass patch-pipettes (Schott #8250 glass, A-M Systems Inc., USA) were pulled (Narishige, PP 830) and polished (Narishige, MF 83) to obtain a final resistance between 2 and 4 MΩ. Patch-pipettes were dialysed with an intracellular solution containing (in mM) the following: 130 KCl, 5 EGTA, 5 MgATP, 10 HEPES (titrated to pH 7.2 with KOH). All recordings were made using an Axopatch 200B amplifier (Axon Instruments, now Molecular Devices) and a CV203B head-stage. Pipette resistance compensation was between 70 and 80%. Data were acquired using a Digidata 1320 interface (Axon Instruments, now Molecular Devices). Data digitization rates were 10–25 kHz during all voltage protocols and an appropriate bandwidth of 2–10 kHz was set on the amplifier.

2.4. Data analysis and statistics

Data analysis was performed using Clampfit 10.3 (Axon Instruments, now Molecular Devices), Prism v4.03 and 5.03 and Excel 2013. Data are presented as the mean ± SEM or as mean with ±95% Confidence Interval (CI). Equations used to fit particular data-sets are given in the online supplement. For statistical analysis, data were subject to the Kolmogorov–Smirnov normality test. Statistical comparisons were made using paired or unpaired two-tailed t tests, Wilcoxon matched pairs signed rank test, Mann–Whitney U test and one way (repeated measures, where indicated) or two way ANOVA, as appropriate. Details of the statistical test used to evaluate significance for results of particular experiments are given alongside “p” values in the Results text or in the relevant table or figure legend. p values less than 0.05 were taken as statistically significant.

2.5. Molecular modelling and docking

A homology model of the open configuration of the hERG channel pore region (pore helix, selectivity filter and S6 helices) based on the crystal structure of MthK channel [38] was used to perform docking simulations with flecainide using GOLD. Further details are provided in the online supplement.

3. Results

3.1. Effect of flecainide on WT hERG in different experimental conditions

Concentration-dependent block of WT \( I_{hERG} \) by flecainide was studied by the repeated application (start-to-start interval of 12 s) of the voltage protocol shown in the lower panel of Fig. 1A (see also [24, 34,37]). Block of \( I_{hERG} \) was assessed by calculating the reduction in drug of the outward ‘tail’ current at —40 mV (assessed as the difference in magnitude between peak tail current and instantaneous current activated by the brief (50 ms) depolarization from —80 to —40 mV [24,34,37]). Flecainide acted rapidly [20], and steady-state inhibition was attained within 3 min of drug application. Fig. 1A shows representative records of WT \( I_{hERG} \) in the absence (control) and in the presence of flecainide (1 μM). The fractional inhibition at each of four concentrations was calculated using Eq. (1) (supplementary information) and the mean values were plotted as shown in Fig. 1D and then fitted with a standard Hill equation (Eq. (2), supplementary information). This yielded a half-maximal inhibitory concentration (IC50) of 1.49 μM (CI: 1.27–1.74) with a Hill coefficient (nH) of 0.81 (CI: 0.68–0.93), in accord with previously observed values under similar experimental conditions [20,24]. Consistent with previous data [20], the inhibitory effect of flecainide on \( I_{hERG} \) exhibited voltage dependence (Fig. S1), with a concomitant leftward shift (—7 mV) in voltage dependent activation. The low expression and kinetics of some mutant channels included in this study requires that \( I_{hERG} \) be studied as an inward current in high (94 mM) \( [K+]_{o} \) [34,35,37]. Consequently, flecainide block of WT \( I_{hERG} \) was also studied under comparable experimental conditions. Fig. 1B and C show the effect of 1 μM flecainide on inward WT \( I_{hERG} \) elicited at —120 mV in normal Tyrode’s and in High \([K+]_{o}\) Tyrode’s respectively; concentration response relations under these conditions are plotted in Fig. 1D. The fits to the experimental data gave an IC50 of 1.05 μM (CI: 0.82–1.38) with a nH of 0.67 (CI: 0.57–0.77) for inward WT \( I_{hERG} \) in normal Tyrode’s solution and an IC50 of 1.25 μM (CI: 0.97–1.60) with a nH of 0.56 (CI: 0.48–0.67) for inward WT \( I_{hERG} \) in High \([K+]_{o}\). Thus flecainide inhibition of \( I_{hERG} \) was not sensitive to the direction/magnitude of \( K^+ \) flux. Under action potential (AP) voltage clamp [37], peak \( I_{hERG} \) during AP repolarization (Fig. 1E) was inhibited by 38.3 ± 1.7% (n = 6), which is not significantly different from the fractional inhibition of the tail current (with the standard protocol) induced by the same drug concentration (41.7 ± 2.2% (n = 21); Fig. 1F, p > 0.05 unpaired t-test).
3.2. Effect of flecainide analogues on WT hERG channels

Membrane “sidedness” of flecainide action was explored using two flecainide analogues used in prior investigation of the drug’s block of sodium channels (Fig. 2A—a fully charged flecainide analogue QX-Flec and the ~90% neutral analogue NU-Flec (pKa 6.3) [39]). We tested the effect of two concentrations (10 and 100 μM) of each analogue applied from the cell exterior (superfusate) and interior (the latter through the patch-pipette). Fig. 2B summarizes the results from the external application of the analogues compared to the parent compound. Sample traces of IhERG elicited by a standard voltage protocol in control and in the presence of 100 μM of QX-Flec and Nu-Flec are shown in Fig. 2Bi and Biii respectively. Each analogue was superfused over the cell under study for 6–8 min and both exhibited a reduction in potency compared to flecainide. For 10 and 100 μM QX-Flec, the fraction of unblocked IhERG was 72.2 ± 4.6% (n = 9) and...
54.6 ± 3.5% (n = 10) respectively, whilst 10 and 100 μM NU-Flec left an unblocked current fraction of 75.8 ± 4.4% (n = 8) and 50.2 ± 4.3% (n = 10) respectively (p < 0.001, one-way ANOVA with Bonferroni post hoc test). Pipette application of two different concentrations of QX-Flec and NU-Flec from the patch-pipette was determined. As soon as the whole-cell configuration was achieved the drug molecules were free to diffuse inside the cytoplasm, precluding cells acting as their own control. Instead, time matched (~6 min) measurements of $I_{\text{HERG}}$ density (with 10 or 100 μM QX-Flec or NU-Flec; Fig. 2Ci) were compared with measurements from cells dialysed with drug-free standard intracellular solution. Fig. 2Ci and Ciii show $I_{\text{HERG}}$ traces after 6 min of internal perfusion with 100 μM QX-Flec and NU-Flec respectively.
Mean values are reported in Fig. 2Ci. When dialyzed with 10 or 100 μM QX-Flec the whole-cell current density was 55.3 ± 5.9 pA/pF (n = 7) and 9.3 ± 1.9 pA/pF (n = 5) respectively, and both values are significantly different from control (315.3 ± 56.7 pA/pF (n = 10), p < 0.05 and p < 0.01 respectively, one-way ANOVA with Bonferroni post hoc).

Conversely, there was no significant difference in lnHecR density between control cells and cells dialyzed with 10 or 100 μM NU-Flec (283.2 ± 63.4 pA/pF (n = 6) and 359.8 ± 56.1 pA/pF (n = 12) respectively, p > 0.05 one-way ANOVA with Bonferroni post hoc). The results of these experiments are consistent with prior data for SCN5A sodium channels, for which both analogues were less effective when applied from the cell exterior, whilst QX-Flec was particularly effective when applied directly to the cell interior [39].

3.3. Relationship between flecainide block and hERG channel inactivation

hiERG inhibition by a number of cardiac and non-cardiac drugs is influenced significantly by channel inactivation (e.g. [31,33,40,41]), although class 1 antiarrhythmic drugs examined to date appear not to depend strongly on inactivation to block the channel [31,33,34]. Fig. 3A and B show the effect of flecainide on hiERG availability, studied with the three-step protocol reported in the inset of Fig. 3Ai [36,42]. The resurgent transient current elicited at the beginning of the third step at +40 mV was analysed as previously described [36,42]. Fig. 3Ai and Aii show sample traces of resurgent IhERG in control and in the presence of 1 μM flecainide (n = 6) and 3.46 ± 0.51 μM flecainide (n = 12) respectively, p > 0.05 one-way ANOVA with Bonferroni post hoc. The results of these experiments are consistent with prior data for SCN5A sodium channels, for which both analogues were less effective when applied from the cell exterior, whilst QX-Flec was particularly effective when applied directly to the cell interior [39].

3.4. Effect of mutations in the hERG pore helix on flecainide potency

A cluster of three residues (T623, S624 and V625) located in the lower portion of pore helix-selectivity filter region has been reported to be involved in the binding to hERG of different drugs (e.g. [43–45]). In order to determine the roles of these residues in flecainide block of hiERG we studied alanine mutants of each of T623, S624 and V625. The T623A mutant was tested in High [K+]o and the current was elicited by a hyperpolarizing step to −120 mV in order to obtain an appreciable inward current transient. The S624A mutant was studied in normal Tyrode’s solution and the current was elicited by the same hyperpolarizing protocol used for T623A [34,37]. Sample traces of T623A, S624A and V625A currents in control and in the presence of 10 μM flecainide are shown in Fig. 5A, B and C respectively. Different flecainide concentrations were tested and a full concentration–response relationship was constructed for each mutant. The derived IC50 are reported in Fig. 5G and Table 1 together with the values from WT hERG under matching experimental conditions (see Fig. 1A–D). The calculated IC50 for T623A was ~5.6-fold that for its WT control. For S624A the IC50 was ~1.8-fold its WT control. The IC50 for V625A was ~2.7-fold its WT control.

3.5. Effect of S6 helix mutations on flecainide potency

To investigate potential binding determinants in the pore region we studied alanine mutants of three residues (G648, Y652 and F656) located within the channel inner cavity on the S6 helix. G648 is a highly conserved residue involved in the binding of high affinity methanesulphonanilide agents [43,44], whilst the aromatic Y652 and F656 residues are of fundamental interest as interactions with at least one of the two have been found to be important for the majority of drugs tested [43–46]. G648A and F656A were studied under the same experimental condition as T623A, whilst V652A was tested in normal Tyrode and the current was elicited by a standard voltage protocol. Sample traces for G648A, Y652A and F656A currents in control and in the presence of 10 μM flecainide are shown in Fig. 5D, E and F, respectively. Different concentrations were tested and the IC50 values from the resulting concentration response relationships are plotted in Fig. 5G for comparison with their respective WT controls, with mean IC50 and nH values given in Table 1. The derived IC50 for G648A was ~9-fold its WT control, that for Y652A was 3.4-fold its WT control and that for F656A was 142-fold its WT control, with an nH of 0.55 (CI: 0.47–0.63). These results support a particularly strong role for the F656 residue in flecainide binding. This was confirmed in further experiments using pipette application of the charged analogue QX–Flec, which produced little inhibition of F656A hERG (see Fig. S2).

3.6. Docking simulation of flecainide with a WT hERG model

Recent studies have proposed different models of flecainide binding to Kv1.2 and Kv1.5 channels [47,48]. In those models flecainide was proposed to interact with potassium sites in the central cavity and with residues located at the subunit interface between S6 and P-helices. Here we tested flecainide on a MthK-based hERG channel model [38] using the docking program GOLD. Several different low energy conformations were obtained that broadly conformed with
the experimental observations; a sample pose is shown in Fig. 6. The molecule tended to adopt an extended conformation, and in most of the low energy poses flecainide docked low in the pore cavity lying between the two aromatic residues F656 and Y652. In this position the piperidine ring and the benzamide moiety of flecainide formed stacking π–π interaction with the surrounding cluster of aromatic rings, in particular with F656 (Fig. 6B). This is consistent with the experimental data in showing a strong dependence of flecainide binding on the presence of the F656 aromatic side chain. This simulation also suggests an allosteric role of V625 residue in the selectivity filter region, since the drug molecule lies too far away to develop a direct interaction with V625. Similar results were obtained in a second series of docking runs using the program Flexidock which better accounts for electrostatic contributions to binding [38] (see Supplement). For other drug molecules Flexidock tends to locate the positively charged portion of the drug closer to the selectivity filter and in or near the binding site for K⁺ ions. However, in our analyses with flecainide most of the low energy conformations had flecainide docked to the inner mouth of the pore interacting mainly with F656 aromatic rings (see Fig. S3).

4. Discussion

Flecainide was originally shown to inhibit feline ventricular E-4031 sensitive delayed rectifier current with an IC₅₀ of 2.1 μM [17,18]. At high concentrations (10 and 30 μM) it was found to inhibit guinea-pig ventricular Iᵥ with selectivity over the slow delayed rectifier current, Iᵥ [19]. Subsequently reported IC₅₀ values for flecainide inhibition of WT IhERG from mammalian expression systems range from 0.74 to 3.91 μM [20,21,24]. The observed potency of flecainide against WT IhERG in the present study falls within this range and is consistent with the potential for direct Iᵥ/IhERG inhibition at clinical concentrations [12]. In addition to exerting an acute inhibitory effect on IhERG, some drugs are also able to impair hERG trafficking [49–51]. Indeed, in one study, 40% (20 of 50) of drugs producing a direct inhibitory effect on IhERG also produced trafficking defects [50]. The focus of the present study was to establish molecular determinants of the acute IhERG inhibitory effects of flecainide; the drug’s effects on hERG channel trafficking were not investigated and remain to be established.

4.1. Gating dependence of flecainide block and intracellular access to the drug binding site

Flecainide has been reported to exhibit both (rapid) time and voltage-dependent inhibition of IhERG [20] and the present study (Fig. S1) affirms voltage-dependence of the drug’s action. The role of inactivation gating in the drug’s action has not hitherto systematically been investigated. The lack of leftward shifted WT IhERG inactivation seen here with flecainide suggests that the drug does not act strongly to stabilize the inactivated state, although the time-course of inactivation was modestly slowed by the drug (Fig. 3). On the other hand, the slower washout of flecainide during sustained depolarization to +40 mV compared to 0 mV, which promoted IhERG inactivation (Fig. 3D, E), suggests that inactivation plays a role in stabilizing the drug within the channel. Our experiments with the S631A and N588K single and double mutations (Fig. 4), yielded an increased IC₅₀ for inhibition of channels with impaired inactivation, which further supports this notion. The ~4–5 fold shift in IC₅₀ with the N588K and S631A mutations and ~13-fold shift for the double mutant compared with an IC₅₀ for IhERG inhibition by the methanesulphonanilide E-4031 that was increased 11–12 fold by the two single mutants and ~36-fold by the N588K/S631A double mutant [33]. Table S1 shows further comparisons of the effects of inactivation mutations on the action of flecainide with comparable values for other class I and III agents. Considered in this context, flecainide inhibition of IhERG shows greater dependence on inactivation than other class I agents studied to date, but less dependence that that observed for methanesulphonanilides.

In a prior study from our laboratory, intracellular dialysis via the patch pipette of flecainide produced less inhibition of IhERG than did extracellular application of the same drug concentration [24]. Additionally, extracellular flecainide block of IhERG was also not sensitive to modification of the pipette solution (although it was to extracellular acidosis). These observations led to a suggestion that flecainide may not access its binding site on the hERG channel from the cell interior [24]. These prior observations are consistent with results on flecainide block of native cardiac Iᵥ and SCN5A-encoded recombinant sodium channels, as — despite acting as an open channel blocker — intracellular flecainide (again applied via the patch pipette) had been reported to be relatively ineffective at inhibiting Iᵥ [39,52]. In experiments using QX-Flec and NU-Flec, Liu and colleagues were able to resolve the membrane ‘sidedness’ of flecainide block and the role of drug ionization in Na channel block [39]. They found that permanently charged flecainide was effective only when applied to the cell interior [39]. Flecainide has a pKa value of 9.3, meaning that the majority, but not all of the parent drug would be expected to be ionized at normal extracellular and intracellular pH values. Liu et al proposed that the apparent ineffectiveness of parent flecainide when applied internally could be explained by a scheme in which the small neutral component of drug leaves the cell by crossing the cell membrane and is then rapidly diluted and washed away by external superfusate, with intracellular re-equilibration/partition between charged and uncharged drug then followed by further uncharged drug egress, leading to dramatic attenuation of action of the pipette-applied flecainide (see [39]). This interpretation may also explain prior observations in respect of pipette applied flecainide on Iᵥ [24]. In our experiments with QX-Flec and NU-Flec on hERG, the former but not latter compound was an effective inhibitor when applied via the patch pipette. The modest component of IhERG inhibition seen when QX-Flec was externally applied is consistent with some passage across the membrane of the quaternary analogue (cf [53]). Thus, the data in the present study are consistent with a scheme in which extracellularly applied flecainide crosses the cell membrane and once inside the cell interior the charged fraction of drug enters the channel on activation gating to exert its inhibitory effect. Independent support for the idea that flecainide acts to inhibit hERG from the cell interior comes from the observation that the drug’s action is potentiated in cells transfected with the drug uptake transporter OCTN1 [22].

4.2. Binding determinants within the hERG inner cavity

High affinity pharmacological inhibition of hERG channels is characterized by drug interactions with a binding site in the inner cavity involving multiple actions with pore-helical and S6 residues (e.g. [43,44,53–55]). For the methanesulphonanilide agent MK499, the Y652A mutation increased the IhERG IC₅₀ 94-fold, whilst F656A increased it 650 fold. G648A resulted in an IC₅₀ 55-fold that of WT IhERG, whilst for T623A, and V625A the corresponding increases were 5 fold and 50 fold, respectively [43]. The related agents E-4031 and dofetilide have similar binding determinants [44]. In contrast, high affinity block by both cisapride and terfenadine has been reported to involve both S6 ar
momatic residues and T623 and S624 pore-helical residues, but not V625, G648 and V659 residues, indicating that different molecules producing high affinity block can adopt distinct binding modes within the channel’s inner cavity [43,54]. By comparison with these drugs, flecainide has a more restricted set of binding determinants. In the case of the cardiac Na channel flecainide shares consensus tyrosine (Y) and phenylalanine (F) binding residues (F1760 and Y1767) on the SCN5A-encoded protein to those of lignocaine [39], whilst for Kv1.5 mutating one of the identified binding determinants, V505, to phenylalana
nine increased blocking potency 9-fold [56]. For flecainide, our data indicate that F656 but not Y652 acts as a key determinant of IhERG inhibi
tion, the crucial role for F656 being further demonstrated by the loss of a significant inhibitory effect of QX-Flec with the F656A mutation. For the class I antiarrhythmic quinidine the F656V mutation increased
the \( I_{hERG} \) IC50 by ~27 fold \[31\], whilst F656A and Y652A mutations increased \( I_{hERG} \) IC50 for disopyramide respectively by ~55 and ~51 fold respectively \[34\], and so flecainide appears to be more sensitive to mutation of F656 than is either of these drugs. In prior experiments using Xenopus oocyte expression, the inhibitory action of the class Ia antiarrhythmic drug ajmaline on \( I_{hERG} \) was greatly impaired by both the
Y652A and F656A mutations, as a profound blocking concentration (for WT hERG; 300 μM) was found to be ineffective against both mutants, from which it is possible to conclude that the Y652 residue plays a more prominent role in the binding of ajmaline than of flecainide [57]. However, as full concentration–response data are not available for ajmaline and these mutants [57], quantitative comparison between ajmaline and flecainide of the relative importance of residue F656 for binding is not possible. To our knowledge, the only other class Ic drug for which hERG binding determinants have been investigated is propafenone [32]. Although structurally distinct from flecainide, propafenone shares with flecainide a relative lack of dependence of hERG block on interactions with Y652 (IC50 6.3-fold that of WT hERG) and a marked dependence on F656 (IC50 ~ 95-fold and ~56-fold the values for WT hERG in low and high [K+]o respectively) [32]. Propafenone showed relatively little sensitivity to T623A, S624A and V625A mutations [32], whilst disopyramide has also been shown to be little affected by T623A and S624A, with only a small effect of V625A [34]. Although the effect of the V625A mutation on flecainide’s IhERG inhibitory action in vitro was marked, the in silico docking in the present study supports an indirect role for this residue as in low energy binding.
Table 1
Effect of pore helix and S6 mutations on IhERG inhibition by flecainide.
The table shows the effects of mutations in the pore-helix/selectivity filter region (T623A, S624A, V625A) and S6 helix (G648A, Y652A, F656A) on IhERG block by flecainide. WT-1, WT-2, WT-3 refer to the 3 conditions under which WT IhERG IC50 values were obtained. For all channel variants, the voltage-step shows the membrane potential at which IhERG tails were measured and the corresponding external potassium ([K+]o) values are given. For each channel/recording condition the mean IC50 and nH values are given and for each mutant, the fold change in IC50 relative to its corresponding WT control is also given (IC50 mutant/IC50 of WT-control).

| Channel  | Voltage step mV | K+ mM | IC50 mean (± 95% CI) μM | nH mean (± 95% CI) | Shift in potency compared to its WT-control |
|----------|-----------------|-------|------------------------|-------------------|---------------------------------------------|
| WT-1     | −40             | 4     | 1.49 (1.27–1.74)        | 0.81 (0.68–0.93)  |                                             |
| WT-2     | −120            | 4     | 1.05 (0.82–1.38)        | 0.67 (0.57–0.77)  |                                             |
| WT-3     | −120            | 94    | 1.25 (0.97–1.6)         | 0.56 (0.48–0.67)  |                                             |
| T623A    | −120            | 94    | 6.97 (5.80–8.38)        | 0.60 (0.54–0.67)  | 5.58                                         |
| S624A    | −40             | 4     | 2.64 (2.30–3.03)        | 1.12 (0.94–1.30)  | 1.77                                         |
| V625A    | −120            | 4     | 28.9 (23.4–35.6)        | 0.71 (0.62–0.80)  | 27.52                                       |
| G648A    | −120            | 94    | 11.1 (9.56–12.8)        | 0.67 (0.61–0.73)  | 8.88                                         |
| Y652A    | −40             | 4     | 5.09 (4.00–6.46)        | 0.60 (0.53–0.68)  | 3.42                                         |
| F656A    | −120            | 94    | 176.9 (143.9–217.3)     | 0.55 (0.47–0.63)  | 141.52                                       |

Fig. 5. Effect of pore-helix and S6 helix mutations on flecainide inhibition of IhERG. (A–C) Upper traces show IhERG elicited by protocols shown as lower traces in control and 10 μM flecainide for the T623A (A), S624A (B) and V625A (C) pore-helical mutants. (D–F) Upper traces show IhERG elicited by protocols shown as lower traces in control and 10 μM flecainide for the G648A (D), Y652A (E) and F656A (F) S6 helix mutants. (G) IC50 for flecainide inhibition of the alanine mutants shown in A–F, together with those for their WT IhERG comparators (WT “Standard” for S624A and Y652A; WT “inward” for V625A; WT “High K+” for T623A, G648A and F656A). Plotted error bars represent 95% confidence intervals. Each IC50 was derived from a concentration–response relationship derived from at least four different drug concentrations, n ≥ 5 for each concentration on each curve.

Fig. 6. In silico docking simulations of flecainide to hERG. (A) Lateral (Ai) and intracellular views (Aii) of a representative low energy pose of flecainide (yellow sticks) docked to an MthK-based open-state hERG channel homology model. Pore region domains are shown as grey ribbons. Green sticks represent residues T623, S624 and V625, whilst Y652 and F656 are shown as pink and blue sticks respectively. K+ ions in the selectivity filter are shown as purple spheres. (B) Representative low energy GOLD pose for flecainide (yellow sticks) docked to hERG pore cavity residues. Residues V625, Y652 and F656 are shown as green, pink and blue sticks, respectively. For clarity only three F656 side chains and three Y652 side chains are shown. The interactions included a π–π interaction (3.7 Å) between the aromatic ring of the benzamide moiety of flecainide and F656, and a second π–π interaction (3.3 Å) between the piperidine ring and an adjacent F656 (black dotted lines).
conformations direct interaction with V625 did not occur. Binding of flecainide relatively low in the pore cavity is further supported by the lack of effect of altering the direction of $K^+$ flux (i.e. lack of a “knock off” effect), which suggests that flecainide is unlikely to lie near the $K^+$ ion conduction pathway. The V625A mutation profoundly attenuates $I_{hERG}$ inactivation [58]. Attenuated inactivation has been proposed to influence drug blocking potency by altering the positioning of S6 aromatic binding residues relative to the inner cavity [59], and this may account for the allosteric effect of V625A on flecainide binding. Support for such an explanation comes from the marked effect of the N588K/ S631A double mutant, which exhibits little inactivation [33], on flecainide block, as neither N588 nor S631 lies near the binding site for flecainide.

4.3. Clinical relevance and implications

As commented in the Introduction text and highlighted by others [5], flecainide’s inhibitory effects on $I_{Na}$ and $I_{K}$ occur at lower concentrations than those on other channels; they are therefore the ion channel effects that are likely to predominate during clinical use of the drug. Until recently, the drug’s effectiveness against CPVT (e.g. [7–10]) has been considered to be a direct consequence of inhibition of RyR2 ryanodine receptors (e.g. [7,60]), which in intact cardiomyocytes would require cell entry of the drug to access RyR2s in the sarcoplasmic reticulum membrane. However, a very recent study has suggested that flecainide does not inhibit luminal-to-cytosolic cation flux through RyR2 and that the drug’s beneficial actions in CPVT are secondary to Na$^+$–dependent modulation of intracellular Ca$^{2+}$ ion handling [61]. The drug’s inhibitory action on Na$^+$ channels may also reduce oxidative stress at high atrial rates through reducing Na$^+$ and, thereby, Ca$^{2+}$ accumulation [5]. Taken together, prior work on Na$^+$ channels using flecainide analogues [39] and the results of the present study indicate that the drug’s actions on its principal ion channel targets in the sarclemmal membrane rely on charged drug access to the target channels from the cell interior.

Although flecainide is recommended as a front-line treatment option for both pharmacological cardioversion and maintenance of sinus rhythm in AF patients [2–4], data from the 2005 Euro Heart Survey on AF suggested that the actual clinical use of the drug is not high (with ~17% and 13% of paroxysmal and persistent AF patients receiving class 1c drug treatment) [5,62]. However, although the results of the CAST trial indicate clearly that flecainide should be avoided in patients with structural heart disease, a review of 25 years of clinical flecainide use suggests that the drug is a safe and effective treatment option for AF in younger patients without concomitant structural heart disease [5]. For example, one systematic review of randomized controlled trials found the incidence of ventricular arrhythmias in AF patients given flecainide to be 3% or less [63]. A meta-analysis of 122 studies of patients receiving flecainide for supraventricular tachycardias, without obvious signs of ventricular damage, found flecainide to be associated with a lower incidence of proarrhythmic events than control (2.7 vs. 4.8%) [64]. Clearly, though, flecainide’s ability to inhibit $I_{hERG}$ at clinically relevant concentrations makes it important to exercise appropriate caution in either very carefully monitoring or avoiding the drug’s administration to patients with other risk factors for acquired LQTS, such as pre-existing QT prolongation, co-administration with other $I_{Na}$/IhERG blocking drugs, or hypokalemia.

5. Conclusions

Flecainide acts as a gated state inhibitor of $I_{hERG}$ at clinically relevant concentrations. Our findings are consistent with a scheme in which flecainide crosses the cell membrane and accesses the channel on activation gating. Our data with QX-Flec and NU-Flec support the notion of preferential interactions between the charged form of the drug and a binding site within the hERG inner cavity. Flecainide exhibits a distinct profile of responses to mutations of amino-acid residues that form the canonical binding site for high affinity inhibitors. It binds low in the inner cavity and interacts strongly with F656. The effect of inactivation gating on flecainide block is likely to result from stabilization of drug binding by optimising drug interactions with F656 aromatic side chains.

Disclosures

None.

Acknowledgements

Funding from the British Heart Foundation is gratefully acknowledged (PS/11/59/28938; PG/10/96/28661; PG/12/69/28784; PG/14/61/31015).

Appendix A. Supplementary data

Supplementary methods information and data to this article can be found online at http://dx.doi.org/10.1016/j.yjmcc.2015.06.021.

References

[1] R.H. Falk, R.I. Fogel, Flecainide, J. Cardiovasc. Electrophysiol. 5 (1994) 964–981.
[2] V. Fuster, L.E. Ryden, R.W. Asinger, D.S. Cannon, H.J. Crijns, R.L. Frier, et al American College of Cardiology/American Heart Association/European Society of Cardiology Board, ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference (committee to develop guidelines for the management of patients with atrial fibrillation); developed in collaboration with the North American Society of Pacing and Electrophysiology, J. Am. Coll. Cardiol. 38 (2001) 1231–1266.
[3] V. Fuster, L.E. Ryden, D.S. Cannon, H.J. Crijns, A.B. Curtis, K.A. Ellenbogen, et al, ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation), Eur. Heart J. 27 (2006) 1979–2030.
[4] L.S. Wann, A.B. Curtis, C.T. January, K.A. Ellenbogen, J.E. Lowe, N.A. Estes III, et al, 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol. 57 (2011) 223–242.
[5] E. Aliot, A. Capucchi, H.J. Crijns, A. Goette, J. Tamargo, Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation, Europace 13 (2011) 161–173.
[6] D.S. Echt, P.R. Liebson, B.L. Mitchell, CAST investigators, Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppres- sion Trial, N E J M 324 (1991) 781–788.
[7] F.A. Hilliard, D.S. Steele, D. Laver, Z. Yang, S.J. Le Marchand, N. Chopra, et al, Flecainide inhibits arrhythmogenic Ca$^{2+}$ waves by open state block of ryanodine receptor Ca$^{2+}$ release channels and reduction of Ca$^{2+}$ spark mass, J. Mol. Cell. Cardiol. 48 (2010) 293–301.
[8] H. Watanabe, N. Chopra, D. Laver, H.S. Hwang, S.S. Davies, D.E. Roach, et al, Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans, Nat. Med. 15 (2009) 380–383.
[9] A. Pflaumer, A.M. Davis, Guidelines for the diagnosis and management of catechol- aminergic polymorphic ventricular tachycardia, Heart Lung Circ. 21 (2012) 96–100.
[10] C. van der Werf, A.H. Zwinderman, A.A. Wilde, Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and fu- ture developments, Europace 14 (2012) 175–183.
[11] J.C. Hancock, K.C.R. Patel, J.W. Jones, Antiarrhythmics — from cell to clinic: past, present and future, Heart 84 (2000) 14–24.
[12] T. Brenzali, Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry, J. Chromatogr. B Biomed. Sci. Appl. 746 (2000) 249–254.
[13] P. Scamps, A. Undrovinas, G. Vassort, Inhibition of $I_{Na}$ in single frog cardiac cells by quinidine, flecainide, ethosuxim and ethazin, Am. J. Physiol. 256 (1989) C549–C550.
[14] D. Mehra, M.S. Imtiaz, D.F. van Helden, B.C. Knollmann, D.R. Laver, Multiple modes of ryanodine receptor 2 inhibition by flecainide, Mol. Pharmacol. 86 (2014) 696–706.
[15] J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, E. Delpon, Pharmacology of cardiac potassium channels, Cardiovasc. Res. 62 (2004) 9–33.
[16] S.W. Yeola, D.J. Sniders, Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current, Cardiovasc. Res. 33 (1997) 540–547.
A.A. Paul, H.J. Witchel, J.C. Hancox, Inhibition of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine, Br. J. Pharmacol. 136 (2002) 717–725.

J. Ducroz, R. Printemps, S. Guilbot, J. Cardette, C. Salvetat, G.M. Le, Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies, J. Pharmacol. Toxicol. Methods 56 (2007) 159–170.

B.F. McBride, T. Yang, K. Liu, T.J. Urban, K.M. Giaconia, R.B. Kim, et al., The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel, J. Cardiovasc. Pharmacol. 54 (2009) 63–71.

A. El Harchi, D. Delmarg, Y.H. Zhang, H. Zhang, J.C. Hancox, Action potential clamp and pharmacology of the variant 1 short QT syndrome T6181 HERG K+ channel, PLoS One 7 (2012) e25451.

C.Y. Du, A. El Harchi, Y.H. Zhang, C.H. Orchard, J.C. Hancox, Pharmacological inhibition of hERG is modulated by extracellular but not intracellular acidosis, J. Cardiovasc. Electrophysiol. 22 (2011) 1163–1170.

J. Thevenin, A. Da Costa, F. Roche, C. Romeyer, M. Messier, K. Isazaf, Flecainide induced ventricular tachycardia (tordases of pointes), Pacing Clin. Electrophysiol. 26 (2003) 1907–1908.

H.S. Kim, H.N. Pak, J.S. Park, S.S. Kim, Flecainide-associated bradyarrhythmia-dependent tordase de pointes: another potential mechanism of proarhythmia, Pacing Clin. Electrophysiol. 36 (2013) e84–e86.

K.N. Oyaoye, O.O. Oyeytao, S.M. Costa, T.A. Mixon, An unusual case of flecainide-induced QT prolongation leading to cardiac arrest, Pharmacotherapy 34 (2014) e30–e33.

K. Hayes, A. Deshmukh, S. Pant, B. Culp, J. Marsh, H. Paydkal, Flecainide associated tordase de pointes: a potential case of reverse use dependence, J. Res. Med. Sci. 18 (2013) 1108–1109.

D.J. Nyders, A. Chaudhary, High affinity open channel block by dovitilide of HERG expressed in a human cell line, Mol. Pharmacol. 49 (1996) 949–955.

Z. Zhou, Q. Gong, B.Y. Z. Fan, J.C. Makiselsi, G.A. Robertson, et al., Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature, Biophys. J. 74 (1998) 230–241.

J.P. Lees-Miller, Y. Duan, G.Q. Teng, H.J. Duff, Molecular determinant of high affinity dovitilide binding to HERG1 expressed in Xenopus oocytes: involvement of 56 sites, Mol. Pharmacol. 57 (2000) 367–374.

H.J. Witchel, C.E. Dempsey, R.B. Sessions, M.D. Perry, J.T. Milines, J.C. Hancox, et al., The low-potency, voltage-dependent HERG channel blocker propafenone — molecular determinants and drug trapping, Mol. Pharmacol. 66 (2004) 1201–1212.

M.J. Perrin, P.W. Kuchel, T.J. Campbell, J.J. Vandenberg, Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go related gene channels, Mol. Pharmacol. 74 (2008) 1443–1452.

Y.H. Zhang, C.K. Coleno, R.B. Sessions, C.E. Dempsey, J.C. Hancox, The HERG K+ channel S4 domain L532P mutation: characterization at 37 °C, Biochim. Biophys. Acta 2011 (1808) 2477–2487.

J.S. Mitcheson, J. Chen, M. Lin, C. Culbosouc, M.C. Sanguinetii, A structural basis for drug-induced long QT syndrome, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12329–12333.

M.J. Perrin, B.S. Zhorov, Homology modeling of Kv1.5 channel block by cationic and electroneutral ligands, Biochim. Biophys. Acta 2013 (2014) 978–987.

M. Madeja, W. Steffen, I. Mesic, B. Garcia, B.S. Zhorov, Overlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1, J. Biol. Chem. 285 (2010) 33898–33905.

S. Rajamani, L.L. Eckhardt, C.R. Valdivia, C.A. Klemens, B.M. Gillman, C.L. Anderson, et al., Drug-induced long QT syndrome: HERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine, Br. J. Pharmacol. 149 (2006) 409–418.

B.A. Wilde, P. Hawryluk, E. Ficker, Y.A. Kuriyesh, G. Kirsch, A.M. Brown, HERG-Lite: a novel comprehensive high-throughput screen for drug-induced HERG risk, J. Pharm. Ther. 55 (2005) 136–142.

I. Staudacher, P.A. Schweizer, H.A. Katus, D. Thomas, HERG protein trafficking and potential for therapy and drug side effects, Curr. Opin. Drug Discov. Devel. 13 (2010) 23–30.

J. Nitta, A. Sunami, F. Marumo, M. Hirosaka, States and sites of actions of flecainide on guinea-pig cardiac sodium channels, Eur. J. Pharmacol. 214 (1992) 191–197.

M. Perry, P.J. Stansfeld, J. Leaney, C. Wood, M.J. de Groot, D. Leishman, et al., Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure–activity relationships of chlofihim and ibutilide analogs, Mol. Pharmacol. 69 (2006) 509–519.

K. Kamiya, R. Niwa, M. Morishima, H. Honjo, M.C. Sanguinetii, Molecular determinants of HERG channel block by terfenadine and cisapride, J. Pharmacol. Sci. 108 (2008) 301–307.

M.C. Sanguinetii, J.S. Mitcheson, Predicting drug–HERG channel interactions that cause acquired long QT syndrome, TIPS 26 (2005) 119–124.

J. Eldstrom, Z. Wang, H. Xu, M. Pourrier, A. Ezrin, K. Gibson, et al., The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels, Mol. Pharmacol. 72 (2007) 1522–1534.

C. Kiesecker, E. Zitron, S. Luck, R. Bloehs, E.P. Scholz, S. Kathofer, et al., Class Ia antiarrhythmic drug ajmaline blocks HERG potassium channels, Naunyn Schmiedeberg's Arch. Pharmacol. 370 (2004) 42–43.

C.C. Siebrands, P. Friederich, Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine, Anesthesiology 106 (2007) 534–541.

J. Chen, G. Seehomh, M.C. Sanguinetii, Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12329–12333.

D. Mehra, M.S. Smitz, D.F. van Helden, B.C. Kollmann, D.R. Laver, Multiple modes of tyramine receptor 2 inhibition by flecainide, Mol. Pharmacol. 86 (2014) 696–706.

M.L. Banister, N.L. Thomas, M.B. Sikkeli, S. Mukherjee, C. Maxwell, K.T. MacLeod, et al., The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2, Circ. Res. 116 (2015) 1324–1335.

R. Nieuwlaat, A. Capucchi, A.J. Camm, S.B. Olsson, D. Andresen, D.W. Davies, et al., Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation, Eur. Heart J. 26 (2005) 2422–2434.

R.L. McNamara, L.J. Tamariz, J.B. Segal, E.B. Basis, Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography, Ann. Intern. Med. 139 (2003) 1018–1033.

M. Weihling, Meta-analysis of flecainide safety in patients with supraventricular tachycardia, Arzneimittelforschung 52 (2002) S514.